by Penelope Macrae
India's biggest drugmaker by sales, Ranbaxy Laboratories, has assured shareholders it is taking "stringent steps" to resolve a US ban on imports of medicines made at its newly renovated showcase plant.
The US Food and Drug Administration (FDA) banned imports last week from Ranbaxy's "ultra modern" Mohali plant, whose renovation was supposed to mark a turning point for the generics giant after years of run-ins with US regulators.
But now Mohali—along with two other Ranbaxy plants placed under FDA bans earlier—are unable to ship to the company's key US market due to for failing to meet "good manufacturing practices".
"Ranbaxy would like to assure all stakeholders we are taking stringent steps to address all (the FDA's) concerns," Ranbaxy chief executive Arun Sawhney told shareholders in a letter posted late Saturday on the company's website.
Ranbaxy is more than 60 percent owned by Japan's Daiichi Sankyo, which bought the firm in 2008 believing its dominance in cheaper generic medicines and developing markets would help the Japanese firm grow sales as Daiichi's drugs came off patent.
It outbid rivals to buy Ranbaxy for $4.6 billion. But its foray into the high-growth copycat drugs arena has brought the Japanese drugmaker only financial pain as the Indian firm has come under fire over a string of safety problems.
New Delhi-based Ranbaxy's shares were trading Friday at 334 rupees—less than half the 737 rupees Daiichi paid in 2008.
The latest FDA ban came just four months after Ranbaxy pleaded guilty to US felony charges of selling adulterated antibiotic, epilepsy and other drugs from the Dewas and Paonta Sahib plants—which are still unable to supply the US market—and paid a record $500 million fine.
The fraud involving the two Indian plants was exposed by an ex-employee who said the 52-year-old company had created "a complicated trail of falsified records and dangerous manufacturing practices".
Announcement of the ban on Mohali's US exports wiped nearly $1 billion off Ranbaxy's share value earlier in the week as a slew of brokerages downgraded the company's earnings prospects.
"We appreciate more is expected from Ranbaxy and will continue to work together with the FDA for an early resolution of their concerns", not only with Mohali but with the other two plants, Sawhney said.
The Mohali plant was gearing up to produce off-patent copies of two blockbuster drugs—Novartis AG's blood-pressure pill Diovan and AstraZeneca Plc's stomach ulcer medicine Nexium.
"The Mohali plant is crucial for (Ranbaxy's) future growth" and the ban "could be a huge setback for the company," said Sarabjit Kour Nangra, a vice-president of Mumbai's Angel Broking.
FDA inspectors found tablets with a "black fibre" suspected to be human hair and pills with apparent machinery oil "black spots" at the Mohali plant. Last year, glass was detected in some pills made at the plant.
A spokesman for Ranbaxy declined Saturday to comment on media reports that the FDA now was scrutinising Ranbaxy's US-based Ohm Laboratories for potentially breaching the US Food, Drug and Cosmetic Act.
Ohm Laboratories is Ranbaxy's only facility making medicines for the US market, even though the company has a total of eight plant sites in India.
The US has traditionally accounted for some 40 percent of Ranbaxy's revenues.
Explore further: India's Ranbaxy promises to address issues over US ban
© 2013 AFP
Medical Xpress on facebook
Related Stories
India's Ranbaxy promises to address issues over US ban
Sep 17, 2013
India's Ranbaxy Laboratories, one of world's biggest generic drug makers, said Tuesday it would take "all necessary steps" to help lift an import ban by the US health regulator on one of its factories.
Indian drugmaker Ranbaxy faces new US regulation woes (Update 2)
Sep 16, 2013
Shares in Indian generic drugs giant Ranbaxy Laboratories crashed by as much as 35 percent on Monday after the US Food and Drug Administration suspended imports from one of its factories.
More pain for Japan's Daiichi hit by Ranbaxy fraud
Jun 09, 2013
Daiichi Sankyo believed it had scored a coup in 2008 when it outbid rivals to buy Indian generics giant Ranbaxy for $4.6 billion but its foray into the high-growth copycat drugs arena has brought the Japanese drugmaker only ...
Ranbaxy recalls generic Lipitor doses
Nov 23, 2012
(AP)—Ranbaxy Pharmaceuticals Inc. has recalled dozens of lots of its generic version of cholesterol drug Lipitor because some may contain tiny glass particles, the latest in a string of manufacturing deficiencies that once ...
India says its drugs safe after generics fraud
Jun 03, 2013
India, known as the "pharmacy to the world", Monday defended its lucrative generic drug industry as safe and strongly regulated after the nation's biggest drug firm pleaded guilty to US charges of making adulterated medicines.
Recommended for you
Lawyers file most isotretinoin adverse drug reports
19 hours ago
(HealthDay)—Attorneys have submitted a disproportionate number of isotretinoin-associated inflammatory bowel disease (IBD) cases to the U.S. Food and Drug Administration, according to a study published ...
Paracetamol improves exercise endurance in the heat
Sep 19, 2013
Paracetamol has a significant effect on exercise performance and the body's ability to cope with the thermal challenge of exercise in the heat, shows a study published today [20 September] in Experimental Physiology.
Elite US Army units stop taking anti-malarial drug
Sep 19, 2013
The top doctor for elite U.S. Army commandos has told troops to immediately stop taking mefloquine, an anti-malaria drug found to cause permanent brain damage in rare cases.
Researchers studying vaccine to prevent potential bird flu pandemic
Sep 19, 2013
Scientists at the University of Maryland School of Medicine's Center for Vaccine Development are part of nationwide vaccine research aimed at protecting adults from a new and virulent strain of avian (bird) influenza (flu) ...
Six myths about vaccines
Sep 19, 2013
Recently released government figures show childhood vaccination has fallen to dangerously low levels in some parts of Australia, resulting in corners of the media claiming that "the vaccine debate" has been ...
Drug approved for treatment of multiple sclerosis
Sep 18, 2013
A transformational new treatment for multiple sclerosis (MS) - the result of over three decades of research in Cambridge - was approved today by the EU agency responsible for regulating new drugs.
User comments
© Medical Xpress 2011-2013, Phys.org network
by Penelope Macrae
India's biggest drugmaker by sales, Ranbaxy Laboratories, has assured shareholders it is taking "stringent steps" to resolve a US ban on imports of medicines made at its newly renovated showcase plant.
The US Food and Drug Administration (FDA) banned imports last week from Ranbaxy's "ultra modern" Mohali plant, whose renovation was supposed to mark a turning point for the generics giant after years of run-ins with US regulators.
But now Mohali—along with two other Ranbaxy plants placed under FDA bans earlier—are unable to ship to the company's key US market due to for failing to meet "good manufacturing practices".
"Ranbaxy would like to assure all stakeholders we are taking stringent steps to address all (the FDA's) concerns," Ranbaxy chief executive Arun Sawhney told shareholders in a letter posted late Saturday on the company's website.
Ranbaxy is more than 60 percent owned by Japan's Daiichi Sankyo, which bought the firm in 2008 believing its dominance in cheaper generic medicines and developing markets would help the Japanese firm grow sales as Daiichi's drugs came off patent.
It outbid rivals to buy Ranbaxy for $4.6 billion. But its foray into the high-growth copycat drugs arena has brought the Japanese drugmaker only financial pain as the Indian firm has come under fire over a string of safety problems.
New Delhi-based Ranbaxy's shares were trading Friday at 334 rupees—less than half the 737 rupees Daiichi paid in 2008.
The latest FDA ban came just four months after Ranbaxy pleaded guilty to US felony charges of selling adulterated antibiotic, epilepsy and other drugs from the Dewas and Paonta Sahib plants—which are still unable to supply the US market—and paid a record $500 million fine.
The fraud involving the two Indian plants was exposed by an ex-employee who said the 52-year-old company had created "a complicated trail of falsified records and dangerous manufacturing practices".
Announcement of the ban on Mohali's US exports wiped nearly $1 billion off Ranbaxy's share value earlier in the week as a slew of brokerages downgraded the company's earnings prospects.
"We appreciate more is expected from Ranbaxy and will continue to work together with the FDA for an early resolution of their concerns", not only with Mohali but with the other two plants, Sawhney said.
The Mohali plant was gearing up to produce off-patent copies of two blockbuster drugs—Novartis AG's blood-pressure pill Diovan and AstraZeneca Plc's stomach ulcer medicine Nexium.
"The Mohali plant is crucial for (Ranbaxy's) future growth" and the ban "could be a huge setback for the company," said Sarabjit Kour Nangra, a vice-president of Mumbai's Angel Broking.
FDA inspectors found tablets with a "black fibre" suspected to be human hair and pills with apparent machinery oil "black spots" at the Mohali plant. Last year, glass was detected in some pills made at the plant.
A spokesman for Ranbaxy declined Saturday to comment on media reports that the FDA now was scrutinising Ranbaxy's US-based Ohm Laboratories for potentially breaching the US Food, Drug and Cosmetic Act.
Ohm Laboratories is Ranbaxy's only facility making medicines for the US market, even though the company has a total of eight plant sites in India.
The US has traditionally accounted for some 40 percent of Ranbaxy's revenues.
Explore further: India's Ranbaxy promises to address issues over US ban
© 2013 AFP
Medical Xpress on facebook
Related Stories
India's Ranbaxy promises to address issues over US ban
Sep 17, 2013
India's Ranbaxy Laboratories, one of world's biggest generic drug makers, said Tuesday it would take "all necessary steps" to help lift an import ban by the US health regulator on one of its factories.
Indian drugmaker Ranbaxy faces new US regulation woes (Update 2)
Sep 16, 2013
Shares in Indian generic drugs giant Ranbaxy Laboratories crashed by as much as 35 percent on Monday after the US Food and Drug Administration suspended imports from one of its factories.
More pain for Japan's Daiichi hit by Ranbaxy fraud
Jun 09, 2013
Daiichi Sankyo believed it had scored a coup in 2008 when it outbid rivals to buy Indian generics giant Ranbaxy for $4.6 billion but its foray into the high-growth copycat drugs arena has brought the Japanese drugmaker only ...
Ranbaxy recalls generic Lipitor doses
Nov 23, 2012
(AP)—Ranbaxy Pharmaceuticals Inc. has recalled dozens of lots of its generic version of cholesterol drug Lipitor because some may contain tiny glass particles, the latest in a string of manufacturing deficiencies that once ...
India says its drugs safe after generics fraud
Jun 03, 2013
India, known as the "pharmacy to the world", Monday defended its lucrative generic drug industry as safe and strongly regulated after the nation's biggest drug firm pleaded guilty to US charges of making adulterated medicines.
Recommended for you
Lawyers file most isotretinoin adverse drug reports
19 hours ago
(HealthDay)—Attorneys have submitted a disproportionate number of isotretinoin-associated inflammatory bowel disease (IBD) cases to the U.S. Food and Drug Administration, according to a study published ...
Paracetamol improves exercise endurance in the heat
Sep 19, 2013
Paracetamol has a significant effect on exercise performance and the body's ability to cope with the thermal challenge of exercise in the heat, shows a study published today [20 September] in Experimental Physiology.
Elite US Army units stop taking anti-malarial drug
Sep 19, 2013
The top doctor for elite U.S. Army commandos has told troops to immediately stop taking mefloquine, an anti-malaria drug found to cause permanent brain damage in rare cases.
Researchers studying vaccine to prevent potential bird flu pandemic
Sep 19, 2013
Scientists at the University of Maryland School of Medicine's Center for Vaccine Development are part of nationwide vaccine research aimed at protecting adults from a new and virulent strain of avian (bird) influenza (flu) ...
Six myths about vaccines
Sep 19, 2013
Recently released government figures show childhood vaccination has fallen to dangerously low levels in some parts of Australia, resulting in corners of the media claiming that "the vaccine debate" has been ...
Drug approved for treatment of multiple sclerosis
Sep 18, 2013
A transformational new treatment for multiple sclerosis (MS) - the result of over three decades of research in Cambridge - was approved today by the EU agency responsible for regulating new drugs.
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment